1. There was no significant difference in efficacy of ICIs in cancer patients with or without AID. 2. Immune-related toxic...
1. Apatinib plus pegylated liposomal doxorubicin led to longer overall survival and progression-free survival, and a higher objective response rate...
1. Overall survival rate at 12 months for the FOLFOX arm and ipilimumab arm was 70% and 57%, respectively. 2....
1. High tumour mutation burden levels were associated with improvements in objective response rate, progression-free survival, and overall survival, with...
1. The circulating tumour DNA-guided approach was non-inferior to the standard clinicopathological approach in terms of 2-year recurrence-free survival. 2....
1. All neoadjuvant dostarlimab patients had a clinical complete response and no patients needed any additional treatments at the study...
1. The median progression-free survival was marginally increased in the atezolizumab group. 2. Adverse events of grades 3 and 4...
1. The adebrelimab group had an improved overall survival, higher objective response rate and an increased progression-free survival. 2. Adverse...
1. Event-free survival and median overall survival were significantly longer in the combination group 2. Febrile neutropenia and infections occurred...
1. Objective response rate was 35%, with 1 patient showing a complete response and 7 showing a partial response. 2....
